Last 7 days
-3.5%
Last 30 days
15.9%
Last 90 days
34.9%
Trailing 12 Months
52.0%
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 529.8M | 551.6M | 574.8M | 0 |
2022 | 486.0M | 489.3M | 496.8M | 509.7M |
2021 | 454.0M | 488.7M | 484.6M | 484.3M |
2020 | 419.3M | 404.5M | 425.3M | 444.4M |
2019 | 308.9M | 342.9M | 378.4M | 408.8M |
2018 | 246.2M | 251.7M | 261.7M | 276.7M |
2017 | 241.8M | 240.9M | 239.3M | 240.3M |
2016 | 136.5M | 175.2M | 210.9M | 244.1M |
2015 | 91.9M | 95.6M | 97.5M | 99.8M |
2014 | 69.0M | 74.1M | 80.4M | 87.1M |
2013 | 60.4M | 60.4M | 63.0M | 66.5M |
2012 | 49.8M | 55.0M | 57.9M | 59.9M |
2011 | 36.6M | 38.9M | 41.2M | 43.5M |
2010 | 0 | 0 | 0 | 34.4M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 01, 2023 | stone warren | sold (taxes) | - | - | -5,431 | president, clinical services |
Nov 17, 2023 | olivo alicia c | sold | -49,082 | 18.39 | -2,669 | general counsel |
Sep 30, 2023 | olivo alicia c | sold (taxes) | - | - | -14.00 | general counsel |
Sep 01, 2023 | olivo alicia c | sold (taxes) | - | - | -1,666 | general counsel |
Aug 01, 2023 | olivo alicia c | sold (taxes) | - | - | -14.00 | general counsel |
Jun 01, 2023 | sikri vishal | sold (taxes) | - | - | -21,406 | president advanced diagnostics |
May 22, 2023 | tetrault lynn a. | acquired | 17,481 | 11.6 | 1,507 | - |
May 01, 2023 | olivo alicia c | sold (taxes) | - | - | -662 | general counsel |
Apr 01, 2023 | kulkarni shashikant | sold (taxes) | - | - | -3,759 | chief scientific officer |
Mar 02, 2023 | dieter cynthia j | sold (taxes) | - | - | -117 | chief accounting officer |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Dec 06, 2023 | CITIGROUP INC | reduced | -44.39 | -915,093 | 678,087 | -% |
Dec 06, 2023 | Raleigh Capital Management Inc. | unchanged | - | -720 | 2,349 | -% |
Dec 04, 2023 | TUCKER ASSET MANAGEMENT LLC | unchanged | - | -754 | 2,460 | -% |
Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 6.95 | -275,374 | 1,242,950 | -% |
Nov 22, 2023 | KBC Group NV | unchanged | - | - | 162,000 | -% |
Nov 22, 2023 | Public Sector Pension Investment Board | reduced | -30.37 | -1,699,570 | 1,939,510 | 0.01% |
Nov 22, 2023 | Graham Capital Management, L.P. | reduced | -33.02 | -453,115 | 476,711 | 0.01% |
Nov 21, 2023 | Walleye Capital LLC | new | - | 331,018 | 331,018 | -% |
Nov 21, 2023 | COMERICA BANK | new | - | 790,053 | 790,053 | -% |
Nov 21, 2023 | COMERICA BANK | sold off | -100 | - | - | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 10, 2023 | artisan partners limited partnership | 0.0% | 10 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 10.83% | 13,674,745 | SC 13G/A | |
Feb 09, 2023 | brown advisory inc | 5% | 6,337,008 | SC 13G | |
Feb 06, 2023 | wellington management group llp | 0.00% | 0 | SC 13G/A | |
Jan 23, 2023 | blackrock inc. | 17.4% | 21,932,623 | SC 13G/A | |
Feb 04, 2022 | wellington management group llp | 8.99% | 11,069,283 | SC 13G | |
Feb 04, 2022 | artisan partners limited partnership | 6.3% | 7,732,355 | SC 13G | |
Jan 27, 2022 | blackrock inc. | 15.7% | 19,328,254 | SC 13G/A | |
Jan 26, 2022 | blackrock inc. | 15.7% | 19,328,254 | SC 13G | |
Feb 10, 2021 | vanguard group inc | 10.06% | 11,167,578 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Dec 05, 2023 | 4 | Insider Trading | |
Nov 20, 2023 | 4 | Insider Trading | |
Nov 17, 2023 | 144 | Notice of Insider Sale Intent | |
Nov 06, 2023 | 8-K | Current Report | |
Nov 06, 2023 | 10-Q | Quarterly Report | |
Oct 03, 2023 | 4 | Insider Trading | |
Sep 05, 2023 | 4 | Insider Trading |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
DHR | 160.7B | 29.6B | 10.51% | -19.98% | 27.16 | 5.44 | -5.39% | -12.54% |
IDXX | 44.1B | 3.6B | 24.23% | 23.99% | 53.65 | 12.3 | 7.43% | 22.86% |
A | 37.3B | 7.0B | 16.28% | -18.61% | 32.89 | 5.33 | 5.03% | -14.68% |
DGX | 15.2B | 9.3B | 1.84% | -9.68% | 19.95 | 1.64 | -9.69% | -38.22% |
EXAS | 11.7B | 2.4B | 2.99% | 40.82% | -41.48 | 4.86 | 19.99% | 60.62% |
MID-CAP | ||||||||
CRL | 10.5B | 4.2B | 16.20% | -2.67% | 22.08 | 2.49 | 11.49% | 8.84% |
MEDP | 8.7B | 1.8B | 2.84% | 34.94% | 31.81 | 4.88 | 29.62% | 20.49% |
NTRA | 6.9B | 988.7M | 40.66% | 50.03% | -13.86 | 7 | 27.41% | 8.51% |
NEOG | 3.9B | 919.1M | 17.21% | 17.06% | -147.97 | 4.28 | 73.02% | -172.93% |
GH | 3.0B | 535.8M | 8.75% | -45.64% | -7.02 | 5.66 | 24.38% | 26.34% |
SMALL-CAP | ||||||||
CDNA | 531.2M | 297.1M | 54.98% | -22.82% | -5.87 | 1.79 | -6.74% | -21.60% |
ACRS | 71.5M | 21.4M | -81.47% | -93.49% | -0.62 | 3.34 | -8.80% | -39.66% |
AWH | 31.2M | 9.2M | -11.33% | -33.68% | -1.76 | 3.4 | 16.43% | 48.38% |
APDN | 12.0M | 13.4M | -4.35% | -39.31% | -1.21 | 0.9 | -26.43% | -20.54% |
BIOC | 120.4K | - | -82.76% | -93.43% | 0 | 0.76 | -57.78% | -93.13% |
Income Statement (Quarterly) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | 3.4% | 151,954,000 | 146,917,000 | 137,220,000 | 138,705,000 | 128,782,000 | 125,072,000 | 117,169,000 | 125,732,000 | 121,340,000 | 121,724,000 | 115,533,000 | 125,997,000 | 125,444,000 | 86,977,000 | 106,030,000 | 106,868,000 | 104,672,000 | 101,713,000 | 95,577,000 | 76,475,000 | 69,097,000 |
Gross Profit | 4.0% | 62,311,000 | 59,891,000 | 54,814,000 | 56,825,000 | 48,893,000 | 43,946,000 | 38,232,000 | 45,257,000 | 47,239,000 | 52,990,000 | 41,574,000 | 57,453,000 | 54,065,000 | 28,006,000 | 46,369,000 | 49,923,000 | 50,832,000 | 48,966,000 | 47,115,000 | 37,111,000 | 32,321,000 |
Operating Expenses | -3.7% | 86,506,000 | 89,785,000 | 89,887,000 | 83,208,000 | 88,403,000 | 83,648,000 | 90,260,000 | 86,824,000 | 86,952,000 | 75,357,000 | 56,681,000 | 51,914,000 | 49,396,000 | 46,913,000 | 51,662,000 | 47,602,000 | 47,173,000 | 44,488,000 | 44,567,000 | 34,289,500 | 28,401,000 |
S&GA Expenses | -6.8% | 17,610,000 | 18,901,000 | 16,259,000 | 17,142,000 | 16,809,000 | 17,071,000 | 16,299,000 | 15,917,000 | 15,704,000 | 17,224,000 | 13,749,000 | 13,105,000 | 11,304,000 | 10,195,000 | 13,258,000 | 12,302,000 | 11,508,000 | 12,324,000 | 11,216,000 | 8,047,000 | 6,900,000 |
R&D Expenses | -29.6% | 5,285,000 | 7,502,000 | 7,395,000 | 6,675,000 | 7,312,000 | 8,626,000 | 7,713,000 | 8,513,000 | 7,409,000 | 3,495,000 | 2,456,000 | 2,100,000 | 1,964,000 | 2,105,000 | 2,060,000 | 2,080,000 | 2,611,000 | 2,587,000 | 1,209,000 | 526,000 | 446,000 |
EBITDA Margin | 20.8% | -0.13 | -0.16 | -0.19 | -0.24 | -0.28 | -0.25 | -0.02 | 0.04 | 0.15 | 0.20 | 0.01 | 0.04 | 0.01 | 0.01 | 0.06 | - | - | - | - | - | - |
Interest Expenses | -12.5% | -2,840,000 | -2,524,000 | 1,467,000 | 441,000 | 139,000 | 926,000 | -1,301,000 | 1,707,000 | 1,296,000 | 902,000 | 1,177,000 | 2,194,000 | 2,458,000 | 1,548,000 | 819,000 | 380,000 | 203,000 | 1,304,000 | 1,826,000 | 1,464,000 | 1,873,000 |
Income Taxes | -27.1% | -2,935,000 | -2,309,000 | -2,925,000 | -2,837,000 | -2,772,000 | -5,730,000 | -3,753,000 | -2,445,000 | -2,822,000 | -2,437,000 | 976,000 | -7,850,000 | -335,000 | -11,132,000 | 1,089,000 | -3,861,000 | 1,348,000 | 175,000 | -2,023,000 | 1,049,000 | 54,000 |
Earnings Before Taxes | 19.5% | -21,451,000 | -26,640,000 | -33,720,000 | -25,524,000 | -39,624,000 | -41,033,000 | -53,161,000 | -44,203,500 | -23,170,000 | 73,436,000 | -21,138,000 | 7,567,000 | 2,222,000 | -17,956,000 | -5,889,000 | 2,435,000 | 3,491,000 | 2,166,000 | -4,447,000 | 1,402,000 | 2,077,000 |
EBT Margin | 17.9% | -0.19 | -0.23 | -0.26 | -0.31 | -0.36 | -0.33 | -0.10 | -0.03 | 0.08 | 0.13 | -0.06 | -0.03 | -0.05 | -0.04 | 0.01 | - | - | - | - | - | - |
Net Income | 23.9% | -18,516,000 | -24,331,000 | -30,795,000 | -22,687,000 | -36,852,000 | -35,303,000 | -49,408,000 | -41,758,500 | -20,348,000 | 75,873,000 | -22,114,000 | 15,417,000 | 2,557,000 | -6,824,000 | -6,978,000 | 6,296,000 | 2,143,000 | 1,991,000 | -2,424,000 | 353,000 | 2,023,000 |
Net Income Margin | 19.4% | -0.17 | -0.21 | -0.24 | -0.28 | -0.33 | -0.30 | -0.07 | -0.02 | 0.10 | 0.15 | -0.02 | 0.01 | -0.01 | -0.01 | 0.01 | - | - | - | - | - | - |
Free Cashflow | -8.1% | -9,771,000 | -9,042,000 | -22,619,000 | -8,219,000 | -24,116,000 | -27,290,000 | -37,259,000 | -31,763,000 | -22,744,000 | -22,737,000 | -13,621,000 | -5,520,000 | -7,331,000 | -3,144,000 | -11,641,000 | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Assets | -1.0% | 1,678 | 1,695 | 1,709 | 1,740 | 1,756 | 1,792 | 1,830 | 1,870 | 1,906 | 1,896 | 1,494 | 988 | 959 | 945 | 732 | 710 | 711 | 697 | 533 | 505 | 455 |
Current Assets | 0.4% | 587 | 585 | 585 | 605 | 603 | 622 | 651 | 682 | 710 | 722 | 943 | 449 | 422 | 419 | 215 | 291 | 292 | 276 | 116 | 104 | 194 |
Cash Equivalents | 5.9% | 306 | 289 | 276 | 263 | 266 | 284 | 306 | 317 | 341 | 369 | 612 | 229 | 233 | 295 | 86.00 | 173 | 179 | 167 | 13.00 | 10.00 | 118 |
Inventory | -3.6% | 24.00 | 25.00 | 24.00 | 24.00 | 24.00 | 22.00 | 24.00 | 23.00 | 22.00 | 21.00 | 21.00 | 30.00 | 21.00 | 22.00 | 20.00 | 14.00 | 13.00 | 9.00 | 10.00 | 9.00 | 7.00 |
Net PPE | -5.6% | 95.00 | 100 | 103 | 102 | 107 | 111 | 109 | 109 | 107 | 112 | 94.00 | 86.00 | 85.00 | 84.00 | 83.00 | 64.00 | 62.00 | 59.00 | 61.00 | 61.00 | 41.00 |
Goodwill | 0% | 523 | 523 | 523 | 523 | 523 | 527 | 527 | 527 | 526 | 267 | 45.00 | 211 | 211 | 211 | 211 | 199 | 199 | 196 | 196 | 198 | 147 |
Liabilities | -1.1% | 731 | 739 | 735 | 742 | 743 | 749 | 755 | 762 | 769 | 748 | 651 | 294 | 293 | 291 | 227 | 202 | 214 | 207 | 209 | 185 | 152 |
Current Liabilities | -2.0% | 93.00 | 95.00 | 87.00 | 90.00 | 85.00 | 83.00 | 82.00 | 87.00 | 93.00 | 99.00 | 68.00 | 73.00 | 65.00 | 62.00 | 68.00 | 64.00 | 69.00 | 59.00 | 73.00 | 61.00 | 47.00 |
Shareholder's Equity | -0.9% | 947 | 956 | 974 | 998 | 1,013 | 1,044 | 1,075 | 1,108 | 1,137 | 1,148 | 844 | 694 | 666 | 654 | 505 | 507 | 497 | 490 | 324 | 320 | 304 |
Retained Earnings | -8.6% | -232 | -214 | -189 | -159 | -136 | -99.55 | -64.24 | -14.84 | 27.00 | 47.00 | -28.60 | -7.18 | -22.60 | -25.16 | -18.33 | -11.36 | -17.65 | -51.69 | -53.68 | -19.36 | -51.56 |
Additional Paid-In Capital | 0.8% | 1,182 | 1,173 | 1,167 | 1,161 | 1,154 | 1,147 | 1,142 | 1,124 | 1,111 | 1,101 | 872 | 701 | 689 | 679 | 526 | 520 | 517 | 543 | 379 | 340 | 354 |
Accumulated Depreciation | 5.0% | 155 | 147 | 139 | 132 | 125 | 123 | 116 | 110 | 112 | 105 | 99.00 | 93.00 | 86.00 | 80.00 | 74.00 | 69.00 | 64.00 | 59.00 | 55.00 | 50.00 | 49.00 |
Shares Outstanding | 0.1% | 127 | 127 | 127 | 127 | 127 | 124 | 124 | 124 | 123 | 118 | 116 | 112 | 110 | 108 | 104 | 105 | 104 | 98.00 | 95.00 | 94.00 | 87.00 |
Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Cashflow From Operations | -255.1% | -5,497 | -1,548 | -12,692 | -3,685 | -16,272 | -16,996 | -29,040 | -19,776 | -7,767 | -1,390 | 2,210 | 5,985 | 526 | 1,882 | -6,933 | 3,359 | 18,634 | -4,721 | 6,097 | 15,453 | 8,381 |
Share Based Compensation | 25.9% | 7,180 | 5,705 | 4,758 | 4,663 | 4,280 | 3,626 | 12,103 | 10,062 | 5,237 | 4,506 | 2,653 | 2,676 | 2,715 | 2,635 | 2,186 | 2,273 | 3,275 | 2,313 | 2,139 | 1,807 | 1,191 |
Cashflow From Investing | 39.3% | 20,821 | 14,949 | 23,742 | -1,063 | -4,198 | -6,274 | 12,052 | -9,583 | -14,686 | -453,410 | -154,688 | -28,854 | -70,716 | -18,163 | -41,708 | -6,076 | -7,316 | -3,042 | -3,196 | -128,596 | -2,148 |
Cashflow From Financing | 2776.6% | 1,841 | 64.00 | 1,379 | 1,802 | 2,959 | 1,011 | 6,057 | 2,460 | -6,720 | 204,610 | 524,935 | 8,265 | 4,115 | 222,600 | 617 | -3,158 | 137 | 162,004 | 483 | 4,547 | 102,785 |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Total net revenue | $ 151,954,000 | $ 128,782,000 | $ 436,091,000 | $ 371,023,000 |
COST OF REVENUE | 89,643,000 | 79,889,000 | 259,075,000 | 239,952,000 |
GROSS PROFIT | 62,311,000 | 48,893,000 | 177,016,000 | 131,071,000 |
Operating expenses: | ||||
General and administrative | 61,486,000 | 64,282,000 | 183,343,000 | 188,481,000 |
Research and development | 5,285,000 | 7,312,000 | 20,182,000 | 23,651,000 |
Sales and marketing | 17,610,000 | 16,809,000 | 52,770,000 | 50,179,000 |
Restructuring charges | 2,125,000 | 0 | 9,883,000 | 0 |
Total operating expenses | 86,506,000 | 88,403,000 | 266,178,000 | 262,311,000 |
LOSS FROM OPERATIONS | (24,195,000) | (39,510,000) | (89,162,000) | (131,240,000) |
Interest (income) expense, net | (2,840,000) | 139,000 | (6,831,000) | 2,366,000 |
Other expense (income), net | 96,000 | (25,000) | (520,000) | 212,000 |
Loss before taxes | (21,451,000) | (39,624,000) | (81,811,000) | (133,818,000) |
Income tax benefit | (2,935,000) | (2,772,000) | (8,169,000) | (12,255,000) |
NET LOSS | $ (18,516,000) | $ (36,852,000) | $ (73,642,000) | $ (121,563,000) |
NET LOSS PER SHARE | ||||
Basic (in dollars per share) | $ (0.15) | $ (0.30) | $ (0.59) | $ (0.98) |
Diluted (in dollars per share) | $ (0.15) | $ (0.30) | $ (0.59) | $ (0.98) |
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | ||||
Basic (in shares) | 125,687 | 124,425 | 125,358 | 124,055 |
Diluted (in shares) | 125,687 | 124,425 | 125,358 | 124,055 |
Clinical Services | ||||
Total net revenue | $ 127,553,000 | $ 106,162,000 | $ 365,578,000 | $ 310,588,000 |
COST OF REVENUE | 73,994,000 | 65,261,000 | 213,032,000 | 197,563,000 |
GROSS PROFIT | 53,559,000 | 40,901,000 | 152,546,000 | 113,025,000 |
Advanced Diagnostics | ||||
Total net revenue | 24,401,000 | 22,620,000 | 70,513,000 | 60,435,000 |
COST OF REVENUE | 15,649,000 | 14,628,000 | 46,043,000 | 42,389,000 |
GROSS PROFIT | $ 8,752,000 | $ 7,992,000 | $ 24,470,000 | $ 18,046,000 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 306,239 | $ 263,180 |
Marketable securities, at fair value | 96,025 | 174,809 |
Accounts receivable, net | 132,640 | 119,711 |
Inventories | 24,053 | 24,277 |
Prepaid assets | 18,676 | 15,237 |
Other current assets | 9,317 | 8,077 |
Total current assets | 586,950 | 605,291 |
Property and equipment (net of accumulated depreciation of $154,840 and $131,930, respectively) | 94,517 | 102,499 |
Operating lease right-of-use assets | 87,131 | 96,109 |
Intangible assets, net | 381,910 | 408,260 |
Goodwill | 522,766 | 522,766 |
Other assets | 4,967 | 5,109 |
Total non-current assets | 1,091,291 | 1,134,743 |
Total assets | 1,678,241 | 1,740,034 |
Current liabilities | ||
Accounts payable | 16,819 | 20,510 |
Accrued compensation | 47,594 | 40,141 |
Accrued expenses and other liabilities | 18,679 | 15,070 |
Current portion of equipment financing obligations | 4 | 70 |
Current portion of operating lease liabilities | 6,213 | 6,584 |
Contract liabilities | 3,617 | 7,557 |
Total current liabilities | 92,926 | 89,932 |
Long-term liabilities | ||
Convertible senior notes, net | 537,475 | 535,322 |
Operating lease liabilities | 62,007 | 68,952 |
Deferred income tax liabilities, net | 25,370 | 34,750 |
Other long-term liabilities | 13,035 | 13,055 |
Total long-term liabilities | 637,887 | 652,079 |
Total liabilities | 730,813 | 742,011 |
Commitments and contingencies (Note 11) | ||
Stockholders’ equity | ||
Common stock, $0.001 par value, (250,000,000 shares authorized; 127,261,476 and 126,913,992 shares issued and outstanding, respectively) | 127 | 127 |
Additional paid-in capital | 1,181,876 | 1,160,882 |
Accumulated other comprehensive loss | (1,846) | (3,899) |
Accumulated deficit | (232,729) | (159,087) |
Total stockholders’ equity | 947,428 | 998,023 |
Total liabilities and stockholders’ equity | $ 1,678,241 | $ 1,740,034 |
 CEO | Mr. Christopher Michael Smith BSc |
---|---|
 WEBSITE | www.neogenomics.com |
 EMPLOYEES | 2100 |